NewsBenzingaExtendicare Q3 Adj. EPS $0.41 Beats $0.36 Estimate, Sales $627.839M Beat $595.300M Estimate Extendicare Q3 Adj. EPS $0.41 Beats $0.36 Estimate, Sales $627.839M Beat $595.300M Estimate Benzinga 2026.11.05 22:56 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide